LECTEVA levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg tablet bottle Austrália - inglês - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: silicon dioxide; calcium hydrogen phosphate; hypromellose; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3.75 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; silicon dioxide; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.375 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; magnesium stearate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.75 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; calcium hydrogen phosphate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; magnesium stearate; hypromellose; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: silicon dioxide; magnesium stearate; hypromellose; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 1.5 mg modified release tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 1.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; hypromellose; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIFROL ER pramipexole dihydrochloride monohydrate 4.5 mg extended-release tablet blister pack Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sifrol er pramipexole dihydrochloride monohydrate 4.5 mg extended-release tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; hypromellose; maize starch; carbomer 941; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.